Contents

Volume 82 Issue 12 | JNNP December 2011

Editorial commentary
1299 Optinurin inclusions in proximal hereditary motor and sensory neuropathy (HMSN-P): familial amyotrophic lateral sclerosis with sensory neuropathy?
M Nakagawa

Neuropsychiatry
1300 Diagnosis and treatment of psychogenic parkinsonism
J Jankovic

1304 Grey matter abnormality in autism spectrum disorder: an activation likelihood estimation meta-analysis study
F Cauda, E Geda, K Sacco, F D’Agata, S Duca, G Geminiani, R Keller

1314 Xenomelia: a new right parietal lobe syndrome
P D McGeoch, D Brang, T Song, R R Lee, M Huang, V S Ramachandran

1320 Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients
A E Cavanaugh, H D Critchley, M Orth, J S Stern, M-B Young, M M Robertson

1324 Delayed experience of volition in Gilles de la Tourette syndrome
G Moreto, P Schwingenschuh, P Katschnig, K P Bhatia, P Haggard

Epilepsy
1328 Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review
L J Bonnett, A Shukralla, C Tudur-Smith, P R Williamson, A G Marson

1334 Detecting deficits of sustained visual attention in delirium

1336 Structural neuroanatomy of face processing in frontotemporal lobar degeneration
R Omans, J D Rohrer, J C Hallstone, J D Warril

Multiple sclerosis
1336 Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
G Edan, G Comi, E Le Page, E Leray, M A Rocca, M Filippi, For The French–Italian Mitoxantrone Interferon-beta-1b Trial Group

1351 Familial recurrence risks for multiple sclerosis in Australia
C O’Gorman, S Freeman, B V Taylor, H Buzzkevuen, Australian and New Zealand MS Genetics Consortium (ANZgene), S A Broadley

1355 Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica

1360 Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes
A Nagashii, M Takaqi, A Umemura, M Tanaka, Y Kitagawa, M Matsui, M Nishizawa, K Sakimura, K Tanaka

Cerebrovascular disease
1365 Factors associated with quality of life in 7-year survivors of stroke
M J Leach, S L Gall, H M Dewey, R A L Macdonell, A G Thirt

1372 Mutations in TGFBR2 cause spontaneous cerebral artery dissection
A Pezzini, B Deora, E Del Zotto, M Ritielli, M Carletti, G Tonellotti, P Bovi, A Gissi, I Volonghi, P Costa, M Magon, A Padowdni, S Barlati, M Colombi
Neurosurgery

1375 Hippocampal resection length and memory outcome in selective epilepsy surgery
C Helmstaedter, S Roeske, S Kaaden, C E Elger, J Schramm

Movement disorders

1382 Urinary dysfunction in early and untreated Parkinson’s disease
T Uchiyama, R Sakakibara, T Yamamoto, T Ito, C Yamaguchi, Y Awa, M Yanagisawa, Y Higuchi, Y Sato, T Ichikawa, T Yamanishi, T Hattori, S Kuwabara

1387 Maximal subthalamic beta hypersynchrony of the local field potential in Parkinson’s disease is located in the central region of the nucleus
C de Solages, B C Hill, H Yu, J M Henderson, H Bronte-Stewart

Neuromuscular disease

1390 Once-weekly risedronate for prevention of hip fracture in women with Parkinson’s disease: a randomised controlled trial
Y Sato, J Iwamoto, Y Honda

1394 Muscle ischaemia in patients with orthostatic hypotension assessed by velocity recovery cycles
A M Humm, H Bostock, R Troller, W J Z’Graggen

Neuro-inflammatory disease

1399 Antiglycine-receptor encephalomyelitis with rigidity
N Mas, A Saiz, M I Leite, P Waters, M Baron, D Castaño, L Sabater, A Vincent, F Graus

PostScript

1402 Letters